Market research
IMU.F ImmunoGen, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- Analyst target
- 9.79
- Dividend yield
- Not available
- Beta
- 1.17
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US45253H1014
- Market cap
- 8B
- Analyst target
- 9.79
- Dividend yield
- Not available
- Beta
- 1.17
About
About ImmunoGen, Inc
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IMU.F discussion.
5 years, 5 months ago
ImmunoGen, Inc is currently in a long term downtrend where the price is trading 10.2% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.7.
ImmunoGen, Inc's total revenue rose by 91.2% to $86M since the same quarter in the previous year.
Its net income has increased by 552.0% to $31M since the same quarter in the previous year.
Finally, its free cash flow grew by 125.8% to $8M since the same quarter in the previous year.
Based on the above factors, ImmunoGen, Inc gets an overall score of 4/5.